Orsiro

Vascular Intervention // Coronary
Drug-Eluting Stent System
 
Orsiro®

Ultrathin struts. Outstanding patient outcomes.



 
 


 
 

 


 

Orsiro
Indicated for discrete de novo stenotic lesions and in-stent restenotic lesions.b

Technical Data


Image

Compliance Chart


Image

Ordering Information


Image

Contact

contact
Country/Region

aø 2.25 – 3.0 mm; bIndication as per IFU; c1 atm = 1.013 bar

1. Based on investigator’s interpretation of BIOFLOW-V primary endpoint results; 2. BIOTRONIK data on file; 3. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis.


Orsiro, proBIO and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies.